We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, NON-U.S. GOV'T
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.
Neurology 2001 November 14
BACKGROUND: Inclusion body myositis (IBM) is the most common acquired disease of muscle in adults over the age of 50 years. Although there is compelling evidence for the importance of immunologic abnormalities in its pathogenesis, the cause of the disease is not known, and it is considered to be resistant to treatment with corticosteroids and other conventional immunosuppressive agents. beta-Interferon (betaIFN), an immunomodulatory cytokine, is a candidate therapeutic agent for IBM.
METHOD: A 24-week, multicenter, randomized, placebo-controlled, parallel-group clinical trial of 30 microg of beta-interferon-1a (betaINF1a) administered IM once a week in 30 patients with IBM was conducted. The primary goal was to establish the safety and tolerability of betaINF1a in IBM. A secondary goal was to obtain preliminary data on the efficacy of betaINF1a by measuring changes from baseline in muscle strength and muscle mass.
RESULTS: Twenty-nine of the 30 subjects enrolled completed the study. Two subjects (one in the placebo group, one in the betaINF1a group) experienced severe adverse events. One subject, randomized to receive betaINF1a, died from an ischemic bowel after resection of a colonic mass. No subjects required dosage reductions, and the adverse event profile was similar for the placebo and betaINF1a groups. There were no significant differences in the changes in muscle strength and muscle mass between the placebo and betaINF1a groups at 6 months.
CONCLUSIONS: betaINF1a at a dose of 30 microg/week IM is well tolerated in IBM. Further studies are needed to establish its therapeutic usefulness in this inflammatory myopathy.
METHOD: A 24-week, multicenter, randomized, placebo-controlled, parallel-group clinical trial of 30 microg of beta-interferon-1a (betaINF1a) administered IM once a week in 30 patients with IBM was conducted. The primary goal was to establish the safety and tolerability of betaINF1a in IBM. A secondary goal was to obtain preliminary data on the efficacy of betaINF1a by measuring changes from baseline in muscle strength and muscle mass.
RESULTS: Twenty-nine of the 30 subjects enrolled completed the study. Two subjects (one in the placebo group, one in the betaINF1a group) experienced severe adverse events. One subject, randomized to receive betaINF1a, died from an ischemic bowel after resection of a colonic mass. No subjects required dosage reductions, and the adverse event profile was similar for the placebo and betaINF1a groups. There were no significant differences in the changes in muscle strength and muscle mass between the placebo and betaINF1a groups at 6 months.
CONCLUSIONS: betaINF1a at a dose of 30 microg/week IM is well tolerated in IBM. Further studies are needed to establish its therapeutic usefulness in this inflammatory myopathy.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app